New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 29, 2014
06:38 EDTACRXAcelRx downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray downgraded AcelRx to Neutral citing an uncertain regulatory outlook for Zalviso after the company received a Complete Response Letter from the FDA. Piper lowered its price target for shares to $8 from $14.
News For ACRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 20, 2015
15:04 EDTACRXAcelRx to reduce workforce by approximately 36%
Subscribe for More Information
15:02 EDTACRXAcelRx names Howard Rosen as interim CEO
AcelRx Pharmaceuticals (ACRX) announced the appointment of Howard Rosen as interim CEO of AcelRx, effective April 1. Rosen is a technically trained executive with over 25 years of success growing start-up and mid-size biopharmaceutical companies. Rosen previously held senior-level general management positions and functional roles in strategy, marketing, finance, business development, and research and development at Gilead Sciences (GILD) and ALZA Corporation. Rosen has served on the Board of Directors of AcelRx since 2008 and currently serves on the Board of Directors of Alcobra and several private biopharmaceutical companies.
March 16, 2015
09:22 EDTACRXOn The Fly: Pre-market Movers
Subscribe for More Information
07:01 EDTACRXAcelRx initiates Phase 3 trial for ARX-04
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use